close

Register today to unlock Valuecruncher and get unlimited access

  • Get unlimited access to all compartors and data
  • Save and share valuations as well as comment on others
  • Alter and save your favourite comparator companies

Already registered? Please login now

Comparison Analysis  

What's this?
Dollar1Point71
Implied share price

Sell Overvalued by 90.6%

5% margin of safety What's this?

EV / Revenue
Use Average
PLX
Protalix BioTherapeutics Inc.
AMGN
Amgen, Inc.
Change
NVO
Novo Nordisk A/S (ADR)
Change
SNY
Sanofi SA (ADR)
Change
GILD
Gilead Sciences, Inc.
Change
3.14 48.12 5.78 1.1 1.78 3.53
All amounts in millions
from last financial year
         
Implied Share Price $1.71 $90.54 $143.53 $78.54 $71.46
Market Cap 1,701 125,122 110,041 108,058 107,944
Net Debt -52 47 -19,392 7,295 7,450
Enterprise Value (EV) 1,656 125,169 118,738 62,150 115,327
Revenue 34 21,662 107,927 34,861 32,639
Balance Sheet          
Total Assets 78 71,449 91,799 102,321 51,716
Total Liabilities 82 43,366 44,830 44,272 33,182
Shareholders Equity -3 28,083 46,969 58,049 18,534.0

Where are the EBIT and EBITDA figures?

Certain companies and those in specific industries (for example insurance) do not report financial results at the EBIT or EBITDA line. For these companies where Valuecruncher does not have EBIT or EBITDA numbers we exclude the valuation metrics driven by these figures. Valuecruncher makes our other valuation metrics available for these companies.

To learn more about comparison analysis, please read our guide to comparison analysis

Comments

No comments yet. Login to comment.